• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: SAMET KENNETH A returned $733,229 worth of Common Stock to the company (19,817 units at $37.00) , closing all direct ownership in the company (withholding tax)

    7/15/21 4:03:40 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care
    Get the next $LMNX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    SAMET KENNETH A

    (Last) (First) (Middle)
    12212 TECHNOLOGY BLVD

    (Street)
    AUSTIN TX 78727

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    LUMINEX CORP [ LMNX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/14/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/14/2021 D 3,000(1) D $37 16,817(2) D
    Common Stock 07/14/2021 D 16,817(3) D $37 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share.
    2. This total includes 197 dividend equivalent shares acquired from the Issuer as follows: 29 shares on 07/09/20, 45 shares on 10/15/20, 43 shares on 01/14/21, 34 shares on 04/15/21, and 46 shares on 07/08/21.
    3. Disposed of pursuant to the Merger Agreement, whereby unvested restricted stock units ("Company RSUs") which were outstanding as of immediately prior to the Effective Time fully vested, and each Company RSU that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes).
    Remarks:
    HARRISS T. CURRIE AS ATTORNEY-IN-FACT FOR KENNETH A. SAMET 07/14/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LMNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LMNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Middlesex Water Set to Join S&P SmallCap 600

    NEW YORK, July 12, 2021 /PRNewswire/ -- Middlesex Water Co. (NASD: MSEX) will replace Luminex Corp. (NASD: LMNX) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, July 15. DiaSorin S.p.A. is acquiring Luminex in a deal expected to be completed soon pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 15, 2021 S&P SmallCap 600 Addition Middlesex Water MSEX Utilities S&P SmallCap 600 Deletion Luminex LMNX Health Care For more information about S&P Dow Jones Indices, please visit www.spdji.com. ABOUT

    7/12/21 6:26:00 PM ET
    $SPGI
    $MSEX
    $LMNX
    Finance: Consumer Services
    Finance
    Water Supply
    Utilities

    Luminex Corporation Declares Second Quarter Cash Dividend

    AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical

    5/20/21 4:30:00 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion

    SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation ((", Luminex", , NASDAQ:LMNX) for a price of USD 37.00 per share in an all-cash transaction. This corresponds to a total equity value of approximately USD 1.8 billion on a fully diluted basis and an enterprise value of approximately USD 1.8 billion. The cash consideration represents a c.23.1% premium to Luminex shareholders based on the unaffected closing stock price of Luminex on 24 February 2021 (the date prior to press rumors regarding a potentia

    4/12/21 10:51:00 AM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    $LMNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Luminex downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Luminex from Overweight to Neutral and set a new price target of $37.00 from $38.00 previously

    4/13/21 11:58:03 AM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    Luminex downgraded by BTIG

    BTIG downgraded Luminex from Buy to Neutral

    4/13/21 7:45:27 AM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    $LMNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Lewis Dijuana K returned $257,335 worth of Common Stock to the company (6,955 units at $37.00) , closing all direct ownership in the company

    4 - LUMINEX CORP (0001033905) (Issuer)

    7/15/21 4:02:22 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    SEC Form 4: MCNAMARA KEVIN M returned $3,713,616 worth of Common Stock to the company (100,368 units at $37.00) , closing all direct ownership in the company to cover withholding tax

    4 - LUMINEX CORP (0001033905) (Issuer)

    7/15/21 4:02:50 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    SEC Form 4: SAMET KENNETH A returned $733,229 worth of Common Stock to the company (19,817 units at $37.00) , closing all direct ownership in the company (withholding tax)

    4 - LUMINEX CORP (0001033905) (Issuer)

    7/15/21 4:03:40 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    $LMNX
    SEC Filings

    View All

    SEC Form 15-12G filed by Luminex Corporation

    15-12G - LUMINEX CORP (0001033905) (Filer)

    7/26/21 4:11:53 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Luminex Corporation

    S-8 POS - LUMINEX CORP (0001033905) (Filer)

    7/14/21 9:27:28 AM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Luminex Corporation

    S-8 POS - LUMINEX CORP (0001033905) (Filer)

    7/14/21 9:24:58 AM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    $LMNX
    Financials

    Live finance-specific insights

    View All

    Luminex Corporation Declares Second Quarter Cash Dividend

    AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical

    5/20/21 4:30:00 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results

    AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP"). CURRENT FINANCIAL HIGHLIGHTS Record revenue for the fourth quarter of $111.4M, a 23% increase over Q4 2019, and record revenue for the year of $417.4M, up 25% vs. 2019, driven primarily by growth associated with the COVID-19 global pandemic Gross margins of 58% for the quarter and 59% for the full year, an improvement of 3 and 4 percentage points, respectively, vs. Q4 and full-year 2019 Operating margin of $10.5M or 9

    2/8/21 4:01:00 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    Luminex Corporation Declares First Quarter Cash Dividend

    AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021 of $0.10 per share of common stock payable on April 15, 2021 to stockholders of record as of the close of business March 25, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We a

    2/8/21 1:00:00 PM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    $LMNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - LUMINEX CORP (0001033905) (Subject)

    2/16/21 11:05:09 AM ET
    $LMNX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - LUMINEX CORP (0001033905) (Subject)

    2/10/21 11:22:44 AM ET
    $LMNX
    Medical/Dental Instruments
    Health Care